Oncolytics BiotechONCY
Market Cap: $73M
About: Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.
Employees: 27
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
17% more funds holding
Funds holding: 35 [Q1] → 41 (+6) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
0.61% less ownership
Funds ownership: 2.33% [Q1] → 1.73% (-0.61%) [Q2]
31% less capital invested
Capital invested by funds: $1.87M [Q1] → $1.3M (-$572K) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Patrick Trucchio 33% 1-year accuracy 45 / 137 met price target | 426%upside $5 | Buy Reiterated | 19 Sept 2024 |
HC Wainwright & Co. Patrick Trucchio 33% 1-year accuracy 45 / 137 met price target | 426%upside $5 | Buy Reiterated | 21 Aug 2024 |